Compare IDEXX Laboratories, Inc. (IDXX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs The Coca-Cola Co K — how do they compare? IDEXX Laboratories, Inc. trades at $573.07 (market cap $46.22B), while The Coca-Cola Co K trades at $86.15 (market cap $372.08B). The key difference: The Coca-Cola Co K is far larger — about 8.1× IDEXX Laboratories, Inc.'s market cap, and The Coca-Cola Co K pays a 2.45% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | KO | |
|---|---|---|
Market Cap | $46.22B | $372.08B |
Sector | Health | Consumer Staples |
52-Week High | $766.68 | $89.08 |
52-Week Low | $526.44 | $65.67 |
Enterprise Value | $47.12B | $399.26B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Coca-Cola (KO) trades at $86.87, down 0.21% today, with a bullish technical signal supported by moving averages and RSI near 69. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains robust profitability with a 28.56% net margin. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
KO offers a solid dividend history with 64 consecutive years of increases, but faces risks from regional demand divergence and high debt. Analysts are bullish with a $95.83 price target, implying 10% upside, though valuation multiples like P/E of 25.97 suggest premium pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
